KALA BIO, Inc. (KALA) |
| 2.23 -0.06 (-2.62%) 05-29 16:00 |
| Open: | 2.42 |
| High: | 2.42 |
| Low: | 2.2 |
| Volume: | 60,422 |
| Market Cap: | 49(M) |
| PE Ratio: | -0.02 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 8.25 |
| Resistance 1: | 5.90 |
| Pivot price: | 2.80 |
| Support 1: | 2.10 |
| Support 2: | 1.75 |
| 52w High: | 1030 |
| 52w Low: | 2.1 |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Financials
| EPS | -165.500 |
| Book Value | 12.560 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -81.6 |
| Return on Equity (ttm) | -279.2 |
Company news
Fri, 22 May 2026
KALA Stock Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
Fri, 15 May 2026
KALA BIO: Q1 Earnings Snapshot - kare11.com
Thu, 07 May 2026
Kala Bio (NASDAQ: KALA) sets 1-for-50 reverse stock split, May 11 start - Stock Titan
Thu, 07 May 2026
KALA BIO (NASDAQ: KALA) files $350M shelf; pivots after failed Phase 2b trial - Stock Titan
Thu, 07 May 2026
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Thu, 07 May 2026
KALA BIO Announces Reverse Stock Split - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
